NCT01536665View on ClinicalTrials.gov

The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

liraglutide

Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.

DRUG

placebo

Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.

Trial Locations (1)

8036

Novo Nordisk Investigational Site, Graz

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01536665 - The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes | Biotech Hunter | Biotech Hunter